Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00953771

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) — TTP  

Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura

Clinical Trial Summary

The purpose of the study is to find out if administration of danazol with plasma exchange and corticosteroids will reduce the number of plasma exchanges required to control Thrombotic Thrombocytopenic Purpura (TTP).

Clinical Trial Description

Danazol is a synthetic steroid hormone structurally resembling a group of natural hormones (androgens)found in the body. Danazol has immune modifying activity and is effective in treatment of blood disorders with low platelet counts such as idiopathic thrombocytopenic purpura (however FDA has not yet approved danazol for this disorder). A study of danazol in conjunction with plasma exchange for thrombotic thrombocytopenic purpura showed that danazol decreased the number of plasma exchanges required by approximately 80% and reduced the time needed to control the disease. It's not clear how danazol works in TTP. It is not approved by the FDA for the treatment of TTP. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00953771
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact
Status Terminated
Phase Phase 2
Start date October 2008
Completion date November 19, 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Recruiting NCT05785468 - A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
Completed NCT04074187 - A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Phase 2/Phase 3
Recruiting NCT01257269 - Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Not yet recruiting NCT05568147 - Aspirin for Prophylaxis of TTP Phase 2/Phase 3
Recruiting NCT05468320 - Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Phase 3
Completed NCT00713193 - Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Completed NCT00426686 - ADAMTS13 in Thrombotic Thrombocytopenic Purpura N/A
Withdrawn NCT00251277 - Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Phase 1/Phase 2
Recruiting NCT04588194 - Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia Phase 2
Active, not recruiting NCT03237819 - Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Phase 3
Completed NCT00907751 - Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Phase 2
Completed NCT03369314 - Observational Study of the Use of octaplasLG®.
Terminated NCT01938404 - Octaplas Adult TTP Trial
Recruiting NCT04981028 - The ConNeCT Study: Neurological Complications of TTP
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Recruiting NCT05389007 - .German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
Withdrawn NCT02626663 - The Role of Microparticles as a Biomarker
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A